Top Analyst Upgrades and Downgrades: DepoMed, Enterprise Products, Expedia, Netflix, Sunrun, Vale and More

Investing

Published: March 10, 2016 8:55 am

Last Updated: January 13, 2020 12:08 pm

Stocks were sharply higher after the European Central Bank set further quantitative easing with more rate cuts (negative rates too) and increased asset purchases. This is driving the S&P over 2,000 and the Dow over 17,000. The first six weeks of 2016 were simply for selling into rallies, but we are now almost at four weeks of rallying.

24/7 Wall St. reviews dozens of analyst reports each morning to find new investing and trading ideas for its readers. Some analyst reports cover stocks to buy, and others cover stocks to sell or avoid.

These are the top analyst upgrades, downgrades and initiations seen on Thursday, March 10, 2016.

DepoMed Inc. (NASDAQ: DEPO) was started as Outperform with a $21 price target (versus a $14.62 prior close) at Leerink. It has a consensus analyst target of $24.70 and a 52-week trading range of $13.27 to $33.74.

Enterprise Products Partners L.P. (NYSE: EPD) was maintained as Outperform with a $30 price target at Credit Suisse. The firm lowered earnings expectations in the call but said that the outlook remains strong. Shares closed at $23.40 and have a $32.17 consensus analyst target and a 52-week range of $19.00 to $34.73.